HOUSE plans to come back to vote on tax, climate bill on Friday Aug. 12 per announcement
— Erik Wasson (@elwasson) August 5, 2022
Ocular Therapeutix Highlights Early Data From Diabetes-Related Eye Disorder
Ocular Therapeutix's Phase 1 HELIOS study unveils Axpaxli's efficacy in treating non-proliferative diabetic retinopathy. Significant DRSS improvement with no worsening observed. Positive Phase 2 data for Paxtrava also disclosed, showing substantial reduction in intraocular pressure.
